ARS Pharmaceuticals frames its intranasal epinephrine spray as a needle-free alternative to products such as EpiPen. Though this spray won the backing of an FDA advisory committee, the agency is now requiring that ARS Pharma run another study to support a regulatory submission.
The drugmaker's generic had originally met with FDA rejection in early 2016, amid a national debate over EpiPen's price.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Mylan evidently subscribes to a "living in the gray" mentality when it comes to business operations.
A healthy dose of competition has been injected into the market for life-saving emergency epinephrine injectors.
Mylan settled with the U.S. Department of Justice to head off potential Medicaid liability claims by federal and state governments.
The abrupt rise is notable because many people think that life-threatening allergies are less common among the elderly. In addition, epinephrine — the active ingredient in EpiPens — can pose greater risks to older adults.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Jimmy Kimmel makes a timely joke about EpiPen during the 68th Annual Emmy Awards he was hosting Sunday night.
High-profile deaths in several states have helped to spur legislative action and fuel demand for consumer-dispensed epinephrine. At the same time, no other company has been able to effectively compete with Mylan’s EpiPen.
Critics say getting generic alternatives to the U.S. market for products like EpiPen is still taking far too long.
From Apple's acquisition of Gliimpse to the story behind Bristol-Myers Squibb's failed Opdivo immunotherapy drug, here were the most-read stories of the week.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
The maker of EpiPen, the life-saving auto-injector for anaphylaxis, is under fire for exorbitant price hikes so much so that even Martin Shkreli called Mylan out for price-gouging last week.
Windgap Medical is moving forward in its development of its EpiPen alternative device with two newly solidified patents.
There must be some better, more efficient solutions for the essential use of the EpiPen, and Windgap Medical is working on it.
As allergies rise, so does the need for on-the-spot epinephrine treatment. Windgap Medical wants to win a chunk of this fast-growing, $1.3 billion market.